Halozyme Therapeutics (HALO) Current Assets (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.0 billion, down 20.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 20.52% YoY), and the FY2025 annual result was $825.2 million, down 23.97% from the prior year.
• Current Assets grew to $1.0 billion in Q1 2026 per HALO's latest filing, from $825.2 million in the prior quarter.
• Over five years, Current Assets peaked at $1.3 billion in Q3 2025 and troughed at $541.9 million in Q2 2022.
• A 5-year average of $914.4 million and a median of $879.0 million in 2023 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets slumped 45.79% in 2022, then jumped 45.41% in 2024.
• A 5-year view of Current Assets shows it stood at $739.0 million in 2022, then rose by 1.0% to $746.4 million in 2023, then jumped by 45.41% to $1.1 billion in 2024, then retreated by 23.97% to $825.2 million in 2025, then rose by 21.55% to $1.0 billion in 2026.
• Business Quant data shows HALO's Current Assets at $1.0 billion in Q1 2026, $825.2 million in Q4 2025, and $1.3 billion in Q3 2025.